RAMP-301 VS-6766-301
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (GOG-3097; ENGOT-ov81/NCRI)
Description: This trial is for patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC), which compares a combination therapy of Avutometinib plus Defactinib versus Investigator’s Choice of Treatment.
Study Phase: Phase 3
Principal Investigator:
Further information